These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 29950211)

  • 21. KIT exon 17 mutations are predictive of inferior outcome in pediatric acute myeloid leukemia with RUNX1::RUNX1T1.
    Srinivasan S; Dhamne C; Patkar N; Chatterjee G; Moulik NR; Chichra A; Pallath A; Tembhare P; Shetty D; Subramanian PG; Narula G; Banavali S
    Pediatr Blood Cancer; 2024 Feb; 71(2):e30791. PubMed ID: 38014874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The immunophenotypic characteristics and flow cytometric scoring system of acute myeloid leukemia with t(8;21) (q22;q22); RUNX1-RUNX1T1.
    Shang L; Chen X; Liu Y; Cai X; Shi Y; Shi L; Li Y; Song Z; Zheng B; Sun W; Ru K; Mi Y; Wang J; Wang H
    Int J Lab Hematol; 2019 Feb; 41(1):23-31. PubMed ID: 30264491
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aberrant co-expression of CD19 and CD56 as surrogate markers of acute myeloid leukemias with t(8;21) in Taiwan.
    Chen SW; Li CF; Chuang SS; Tzeng CC; Hsieh YC; Lee PS; Chen CH; Huang WT; Hwang WS; Tsao CJ
    Int J Lab Hematol; 2008 Apr; 30(2):133-8. PubMed ID: 18333845
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Usefulness of KIT mutant transcript levels for monitoring measurable residual disease in t (8;21) acute myeloid leukemia.
    Sun Y; Wang X; Chen WM; Hao Y; Li LD; Li JY; Sun K; Shi ZY; Jiang H; Jiang Q; Huang XJ; Qin YZ
    Hematol Oncol; 2024 Mar; 42(2):e3264. PubMed ID: 38461410
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD56 and RUNX1 isoforms in AML prognosis and their therapeutic potential.
    Zaidi SZ; Motabi IH; Al-Shanqeeti A
    Hematol Oncol Stem Cell Ther; 2016 Sep; 9(3):129-30. PubMed ID: 26706848
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A minicircuitry of microRNA-9-1 and RUNX1-RUNX1T1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia.
    Fu L; Shi J; Liu A; Zhou L; Jiang M; Fu H; Xu K; Li D; Deng A; Zhang Q; Pang Y; Guo Y; Hu K; Zhou J; Wang Y; Huang W; Jing Y; Dou L; Wang L; Xu K; Ke X; Nervi C; Li Y; Yu L
    Int J Cancer; 2017 Feb; 140(3):653-661. PubMed ID: 27770540
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mediation analysis reveals common mechanisms of RUNX1 point mutations and RUNX1/RUNX1T1 fusions influencing survival of patients with acute myeloid leukemia.
    Hornung R; Jurinovic V; Batcha AMN; Bamopoulos SA; Rothenberg-Thurley M; Amler S; Sauerland MC; Berdel WE; Wörmann BJ; Bohlander SK; Braess J; Hiddemann W; Lehmann S; Mareschal S; Spiekermann K; Metzeler KH; Herold T; Boulesteix AL
    Sci Rep; 2018 Jul; 8(1):11293. PubMed ID: 30050054
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA.
    Duployez N; Nibourel O; Marceau-Renaut A; Willekens C; Helevaut N; Caillault A; Villenet C; Celli-Lebras K; Boissel N; Jourdan E; Dombret H; Figeac M; Preudhomme C; Renneville A
    Am J Hematol; 2014 Jun; 89(6):610-5. PubMed ID: 24616160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. AML with RUNX1::RUNX1T1 Cooperating two Mutations Relapsed Quickly after Achieving CR.
    XinhongYang ; Wu Y; Yang X; Wu X; Chen Y; Zhang R; Zhang Z
    Clin Lab; 2024 Mar; 70(3):. PubMed ID: 38469780
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Immunophenotypic Analysis of Patients with CD56⁺ Acute Myeloid Leukemia].
    Guo R; Shen AL; Wang Y; Liu L; Zhang JF; Wang R; Li JY; Wu YJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1231-4. PubMed ID: 26524014
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effect of WT1 Gene High Expression and CD34
    Hu ZL; Huang BJ; Pan SJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Dec; 24(6):1670-1674. PubMed ID: 28024475
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effect of Signal Transduction Pathway Gene Mutations on the One- course Induced Remission Rate and Analysis of Clinical Characteristics in Patients with CBF-AML].
    Fan LF; Xu J; Chen XH; Tian TT; Xie J; Hu JJ; Guo ZP; Tan YH; Xu ZF; Ren FG; Zhang YF; Luo M; Ren WX; Wang HW
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Jun; 28(3):781-788. PubMed ID: 32552936
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.
    Qin YZ; Wang Y; Zhu HH; Gale RP; Zhang MJ; Jiang Q; Jiang H; Xu LP; Chen H; Zhang XH; Liu YR; Lai YY; Jiang B; Liu KY; Huang XJ
    Chin J Cancer; 2016 May; 35():46. PubMed ID: 27197573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic Significance of CD56 Antigen Expression in Patients with
    Sun Y; Wan J; Song Q; Luo C; Li X; Luo Y; Huang X; Ding R; Li H; Hou Y; Huang Y; Xie M; Huang Z; Zhang Y; Ma Y; Wu G; Xu S; Chen J
    Biomed Res Int; 2021; 2021():1929357. PubMed ID: 33928145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations.
    Tang JL; Hou HA; Chen CY; Liu CY; Chou WC; Tseng MH; Huang CF; Lee FY; Liu MC; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Lin LI; Tien HF
    Blood; 2009 Dec; 114(26):5352-61. PubMed ID: 19808697
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Relevance of RUNX1 and CBFB Alterations in Acute Myeloid Leukemia and Other Hematological Disorders.
    Metzeler KH; Bloomfield CD
    Adv Exp Med Biol; 2017; 962():175-199. PubMed ID: 28299658
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Correlations Between
    Wang XM; Ye YX; Yang L; Lu XJ; Ying BW
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2016 Nov; 47(6):931-935. PubMed ID: 28598127
    [TBL] [Abstract][Full Text] [Related]  

  • 38. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.
    Kim HJ; Ahn HK; Jung CW; Moon JH; Park CH; Lee KO; Kim SH; Kim YK; Kim HJ; Sohn SK; Kim SH; Lee WS; Kim KH; Mun YC; Kim H; Park J; Min WS; Kim HJ; Kim DH;
    Ann Hematol; 2013 Jan; 92(2):163-71. PubMed ID: 23053179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Two cases of systemic mastocytosis with RUNX1-RUNX1T1 positive acute myeloid leukemia treated with sequential avapritinib after allogeneic hematopoietic stem cell transplantation and literature review].
    Wang J; Zu YL; Gui RR; Li Z; Zhang Y; Zhou J
    Zhonghua Xue Ye Xue Za Zhi; 2024 May; 45(5):505-508. PubMed ID: 38964927
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute myeloid leukemia with del(X)(p21) and cryptic RUNX1/RUNX1T1 from ins(8;21)(q22;q22q22) revealed by atypical FISH signals.
    Jang JH; Yoo EH; Kim HJ; Kim DH; Jung CW; Kim SH
    Ann Clin Lab Sci; 2010; 40(1):80-4. PubMed ID: 20124335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.